Gilead Sciences (NASDAQ:GILD) underwent analysis by 11 analysts in the last ... with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...

There are 2,823 funds or institutions reporting positions in Gilead Sciences. This is an decrease of 75 owner(s) or 2.59% in the last quarter. Average portfolio weight of all funds dedicated to ...

In the latest market close, Gilead Sciences (GILD) reached $85.21, with a +0.92% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.97%.

Shares of Gilead Sciences Inc. GILD inched 0.33% higher to $84.95 Friday, on what proved to be an all-around great trading ...

Success in this area could pave the way for further expansion in liver diseases and demonstrate Gilead's ability to effectively diversify its portfolio through strategic acquisitions. Gilead Sciences ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $77.91, along ...

“We look forward to sharing new research that highlights the breadth of our antiviral portfolio and expanding pipeline as ... Virology Therapeutic Area Head at Gilead Sciences. “The data reflect our ...

“We look forward to sharing new research that highlights the breadth of our antiviral portfolio and expanding ... Virology Therapeutic Area Head at Gilead Sciences. “The data reflect our ...

--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq ... to sharing new research that highlights the breadth of our antiviral portfolio and expanding pipeline as we strive to treat, prevent, cure ...